The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Novartis; Roche/Genentech; TG Therapeutics
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen-Cilag; Loxo/Lilly; Merck; Roche/Genentech (Inst); TG Therapeutics
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche
BRUIN MCL-321: A phase 3, open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma.
 
Michael Wang
Honoraria - Abbvie; Acerta Pharma; AstraZeneca; Bantam Pharmaceutical; BeiGene; Bioinvent; Breast-Gynecological International Cancer Society; Bristol Myers Squibb Foundation; CAHON; Dava Oncology; Eastern Virginia Medical School; Genmab; IDEOlogy Health; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; MD Education; Medscape; Meeting Minds Experts; Merck; Moffit Cancer Center; Nurix; OncLive/MJH Life Sciences; Oncology Specialty Group; Pharmacyclics/Janssen; Physicans' Education Resource; Practice Point Communications; Studio ER Congressi
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; Amphista Therapeutics; AstraZeneca; Be Biopharma; BeiGene; Bioinvent; Deciphera; DTRM; Genentech; Innocare; Janssen Research & Development; Kite, a Gilead company; Leukemia and Lymphoma Society; Lilly; Merck; Milken Institute; Miltenyi Biomedicine; Oncternal Therapeutics; Parexel; Pepromene; Pepromene; Pharmacyclics/Janssen; VelosBio
Research Funding - Acerta Pharma; AstraZeneca; BeiGene; Bioinvent; Celgene; Genentech; Genmab; Innocare; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Lilly; Loxo; Molecular Templates; Oncternal Therapeutics; Pharmacyclics; VelosBio; Vincerx Pharma
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Kite, a Gilead company; Physicans' Education Resource
 
Toby A. Eyre
Honoraria - Abbvie; AstraZeneca; Gilead Sciences; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Gilead Sciences; Incyte; Kite/Gilead; Loxo/Lilly; Roche; Secura Bio
Speakers' Bureau - Abbvie; AstraZeneca; Incyte; Kite/Gilead; Loxo/Lilly; Medscape; Peerview; Roche
Research Funding - AstraZeneca; BeiGene
Expert Testimony - Abbvie; AstraZeneca; BeiGene; Incyte; Kite/Gilead; Loxo/Lilly; Roche; Secura Bio
Other Relationship - Loxo/Lilly
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Steven Le Gouill
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Martin H. Dreyling
Consulting or Advisory Role - Abbvie/Genentech (Inst); Acerta Pharma/AstraZeneca; Amgen; Bayer/Vital; Beigene; Celgene/Jazz; Genmab; Gilead Sciences; Incyte; Janssen-Cilag; Lilly Medical; morphosys; Novartis; Roche
Speakers' Bureau - Amgen; Bayer Health; Beigene; Celgene; Gilead Sciences; Janssen-Cilag; Roche Pharma AG
Research Funding - Abbvie (Inst); Bayer (Inst); Celgene (Inst); Janssen-Cilag (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag; Roche Pharma AG
 
Elisabeth Vandenberghe
No Relationships to Disclose
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Chan Cheah
No Relationships to Disclose
 
Yuqin Song
No Relationships to Disclose
 
Mitul Gandhi
Honoraria - GlaxoSmithKline; Janssen Oncology (Inst); Karyopharm Therapeutics; TG Therapeutics
 
Christopher H. Chay
No Relationships to Disclose
 
Jeff Porter Sharman
Employment - US Oncology Network
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Beigene; Beigene; Bristol-Myers Squibb; Genentech; Janssen Oncology; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
David Jacob Andorsky
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Bristol-Myers Squibb/Celgene
Research Funding - Abbvie; Bristol-Myers Squibb/Celgene; Epizyme; TG Therapeutics
 
Amy S. Ruppert
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
Other Relationship - Telios
 
Chi-Wei Duann
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Valerie A. Muthig
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Rodrigo Ito
Employment - Loxo@Lilly
Stock and Other Ownership Interests - Lilly O.
 
Wojciech Jurczak
Consulting or Advisory Role - AstraZeneca; BeiGene; Roche
Research Funding - Acerta Pharma; BeiGene; Epizyme; Janssen-Cilag; MEI Pharma; Morphosys; Roche; Sandoz-Novartis; Takeda; TG Therapeutics; TG Therapeutics